keyword
MENU ▼
Read by QxMD icon Read
search

interim Pet hodgkin

keyword
https://www.readbyqxmd.com/read/29156718/interleukin-31-and-thymic-stromal-lymphopoietin-expression-in-plasma-and-lymph-node-from-hodgkin-lymphoma-patients
#1
Elisa Ferretti, Stefan Hohaus, Arianna Di Napoli, Beatrice Belmonte, Annarosa Cuccaro, Elisa Cupelli, Eugenio Galli, Vittoria Rufini, Gino Tripodi, Giulio Fraternali-Orcioni, Vito Pistoia, Anna Corcione
Hodgkin Lymphoma (HL) is a tumor of B-cell origin characterized by Hodgkin and Reed-Stenberg (H/RS) cells embedded in an inflammatory tissue where numerous cytokines/chemokines contribute to shape the microenvironment, leading to the typical clinical symptoms. We investigated: i) the expression of Interleukin-IL-31 (IL-31) and Thymic Stromal Lymphopoietin (TSLP), two Th2-related cytokines with tumor-promoting and pruritogenic functions, and of the respective receptors in HL invaded lymph nodes by flow cytometry, and ii) the potential association of IL-31/TSLP plasma concentrations with clinical characteristics by ELISA...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29045539/the-predictive-value-of-interim-fdg-pet-in-early-stage-hodgkin-lymphoma-is-not-well-established
#2
H J A Adams, T C Kwee
No abstract text is available yet for this article.
October 11, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28992524/early-reduction-of-serum-tarc-levels-may-predict-for-success-of-abvd-as-frontline-treatment-in-patients-with-hodgkin-lymphoma
#3
A Guidetti, A Mazzocchi, R Miceli, E Paterno', F Taverna, F Spina, F Crippa, L Farina, P Corradini, A M Gianni, S Viviani
BACKGROUND: Many efforts have been made to predict prognosis of newly diagnosed Hodgkin Lymphoma (HL) patients. Objective of this study was to investigate the association between early reduction of Thymus and Activation-Regulated Chemokine after the first ABVD cycle (TARC-1) and prognosis of HL patients. METHODS: Serum samples of 116 HL patients were collected at baseline, after every ABVD cycle and during follow-up. The 99th centile of TARC distribution in a group of 156 independent healthy subjects (800pg/ml) was considered as cut-off for discriminating between abnormal and normal TARC values...
November 2017: Leukemia Research
https://www.readbyqxmd.com/read/28989291/frontline-therapy-for-classical-hodgkin-lymphoma-by-stage-and-prognostic-factors
#4
REVIEW
Pamela B Allen, Leo I Gordon
Hodgkin lymphoma is a highly curable malignancy in early and advanced stages. Most patients are diagnosed in their teens or twenties and are expected to live decades beyond their treatment. Therefore, the toxicity of treatment must be balanced with the goal of cure. Thus, treatment has been refined through prognostic models and positron emission tomography-computed tomography (PET-CT)-directed therapy. Stratification by prognostic models defines groups of patients with favorable characteristics who may be treated with less intensive therapy upfront, including fewer cycles of chemotherapy, lower doses of radiation, or omission of radiation altogether...
2017: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/28978839/treatment-strategy-for-patients-with-hodgkin-lymphoma
#5
Isao Yoshida
Although Hodgkin lymphoma is a disease with a low incidence rate, there is a significant social resources perspective associated with this disease to ensure that adolescents and young adults are adequately treated and receive social reintegration. Consequently, Hodgkin lymphoma is considered an important disease in the field of oncology. Combined modality therapy, which combines chemotherapy and radiotherapy, has resulted in cure rates of more than 80% in patients with early stages of this disease, although long-term sequelae remain a problem...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28950332/the-predictive-role-of-interim-pet-after-the-first-chemotherapy-cycle-and-sequential-evaluation-of-response-to-abvd-in-hodgkin-lymphoma-patients-the-polish-lymphoma-research-group-plrg-observational-study
#6
J M Zaucha, B Malkowski, S Chauvie, Subocz E, J Tajer, Kulikowski W, A Fijolek-Warszewska, A Biggi, F Fallanca, M Kobylecka, M Dziuk, D Woszczyk, J Rybka, R Kroll-Balcerzak, F Bergesio, A Romanowicz, A Chamier-Cieminska, P Kurczab, A Giza, K Lesniewski-Kmak, R Zaucha, D Swietlik, T Wróbel, W Knopinska-Posluszny, J Walewski, A Gallamini
Background: Interim PET after 2 ABVD cycles (iPET2) predicts treatment outcome in classical Hodgkin lymphoma (cHL). To test if an earlier assessment of chemosensitivity would improve the prediction accuracy, we launched a prospective, multicenter observational study aimed at assessing the predictive value (PV) of iPET after 1 ABVD (iPET1) and the kinetics of response assessed by sequential PET scanning. Patients and Methods: Consecutive patients with newly diagnosed cHL underwent interim PET scan after one ABVD course (iPET1)...
September 18, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28947879/the-role-of-fdg-pet-in-hodgkin-lymphoma
#7
REVIEW
Edyta Subocz, Janusz Hałka, Mirosław Dziuk
18-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/computed tomography (CT) is currently the most valuable imaging technique in Hodgkin lymphoma. Since its first use in lymphomas in the 1990s, it has become the gold standard in the staging and end-of-treatment remission assessment in patients with Hodgkin lymphoma. The possibility of using early (interim) PET during first-line therapy to evaluate chemosensitivity and thus personalize treatment at this stage holds great promise, and much attention is now being directed toward this goal...
2017: Contemporary Oncology Współczesna Onkologia
https://www.readbyqxmd.com/read/28898338/-response-to-abvd-chemotherapeutic-protocol-in-patients-with-early-stage-hodgkin%C3%A2-s-lymphoma
#8
Javier Díaz, Katherine Soto, Daniel Ernst
BACKGROUND: Recent trials show that > 90% of patients with early stage Hodgkin`s Lymphoma (ESHL) can be cured, especially when using the ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapeutic (CT) protocol. The use of radiotherapy (RT) is variable and can be selected according to the presence of specific risk factors, including PET-CT, as recently reported. AIM: To report the experience in the treatment of ESHL. MATERIAL AND METHODS: Retrospective and descriptive analysis of patients with ESHL treated at the Red de Salud UC-Christus between 2011-2015...
May 2017: Revista Médica de Chile
https://www.readbyqxmd.com/read/28867113/precision-medicine-and-pet-computed-tomography-in-pediatric-malignancies
#9
REVIEW
Yasemin Sanli, Ebru Yilmaz, Rathan M Subramaniam
Fluorine-18 fluorodeoxyglucose ((18)F-FDG) PET-computed tomography (CT) plays a significant role in diagnosis, staging, therapy selection, and therapy assessment of multiple pediatric malignancies and facilitating precision medicine delivery in pediatric patients. In patients with Hodgkin lymphoma, interim fludeoxyglucose (18)F-FDG PET/CT is highly sensitive and specific for predicting survival and multiple trials with FDG PET/CT-based adaptive therapies are currently ongoing. It is superior to iodine-131 metaiodobenzylguanidine ((131)I-MIBG) scintigraphy and bone scintigraphy for detecting metastases in neuroblastoma patients and sarcoma patients...
October 2017: PET Clinics
https://www.readbyqxmd.com/read/28864629/predictive-value-of-pet-response-combined-with-baseline-metabolic-tumor-volume-in-peripheral-t-cell-lymphoma-patients
#10
Anne-Segolene Cottereau, Tarec C El-Galaly, Stéphanie Becker, Florence Broussais, Lars Jelstrup Peterson, Christophe Bonnet, John O Prior, Herve Tilly, Martin Hutchings, Olivier Casasnovas, Michel A Meignan
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphomas with poor outcomes with current therapy. We investigated if response assessed with Positron Emission Tomography/computed tomography (PET/CT) combined with baseline total metabolic tumor volume (TMTV) could detect early relapse/refractory patients. Methods: 140 patients with nodal PTCL who underwent baseline PET/CT were selected from 7 European centers. 43 had interim PET (iPET) performed after two cycles (iPET2), 95 after 3 or 4 cycles (iPET3/4) and 96 had end of treatment PET (eotPET)...
September 1, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28832956/early-stage-hodgkin-lymphoma-outcomes-after-combined-modality-therapy-according-to-the-post-chemotherapy-5-point-score-can-residual-pet-positive-disease-be-cured-with-radiotherapy-alone
#11
Sarah A Milgrom, Chelsea C Pinnix, Hubert Chuang, Yasuhiro Oki, Mani Akhtari, Osama Mawlawi, Naveen Garg, Jillian R Gunther, Jay P Reddy, Grace L Smith, Eric Rohren, Frederick B Hagemeister, Hun J Lee, Luis E Fayad, Wenli Dong, Eleanor M Osborne, Zeinab Abou Yehia, Michelle Fanale, Bouthaina S Dabaja
Early-stage classical Hodgkin lymphoma (HL) patients are evaluated by an end-of-chemotherapy positron emission tomography-computed tomography (eoc-PET-CT) after doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) and before radiation therapy (RT). We determined freedom from progression (FFP) in patients treated with ABVD and RT according to the eoc-PET-CT 5-point score (5PS). Secondarily, we assessed whether patients with a positive eoc-PET-CT (5PS of 4-5) can be cured with RT alone. The cohort comprised 174 patients treated for stage I-II HL with ABVD and RT alone...
November 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28768246/interim-pet-ct-may-predict-pfs-and-os-in-t-all-lbl-adult-patients
#12
Liang Wang, Jing-Hua Wang, Xi-Wen Bi, Xiao-Qin Chen, Yue Lu, Zhong-Jun Xia
T lymphoblastic leukemia/lymphoma (T-ALL/LBL) is highly aggressive. Although intensive chemotherapies such as ALL-type regimens are commonly used, about half adult patients eventually relapse and die of T-ALL/LBL. Overwhelming evidences have confirmed that interim PET can predict survival outcomes and guide subsequent treatments in Hodgkin lymphoma. However, whether interim PET-CT can predict survival outcomes or not in T-ALL/LBL patients remains unclear. 47 adult patients of T-ALL/LBL were retrospectively reviewed...
July 26, 2017: Oncotarget
https://www.readbyqxmd.com/read/28760308/real-life-experience-for-integration-of-pet-ct-in%C3%A2-the-treatment-of-hodgkin-lymphoma-in%C3%A2-lebanon
#13
Riwa Sakr, Marcel Massoud, Fouad Kerbage, Layale Rached, Jean Zeghondy, Elie Akoury, Fady Nasr, Georges Chahine
BACKGROUND: Hodgkin lymphoma (HL) is a highly curable disease; < 80% of patients will achieve long-term survival. Positron emission tomography-computed tomography (PET-CT) has played a major role in the evaluation of both disease staging and response and has become an essential component in tailoring patients' treatment. We report the effect of integrating PET-CT into the management of HL in Lebanon. PATIENTS AND METHODS: We analyzed the data regarding the usage of PET-CT at diagnosis, during treatment (interim PET), and at the end of treatment...
July 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28750493/concomitant-semi-quantitative-and-visual-analysis-improves-the-predictive-value-on-treatment-outcome-of-interim-18f-fluorodeoxyglucose-positron-emission-tomography-in-advanced-hodgkin-lymphoma
#14
Alberto Biggi, Fabrizio Bergesio, Stephane Chauvie, Andrea Bianchi, Massimo Menga, Federico Fallanca, Martin Hutchings, Michele Gregianin, Michel Meignan, Andrea Gallamini
BACKGROUND: Qualitative assessment using the Deauville five-point scale (DS) is the gold standard for interim and end-of treatment PET interpretation in lymphoma. In the present study we assessed the reliability and the prognostic value of different semi- quantitative (SQ) parameters in comparison with DS for interim PET (iPET) interpretation in Hodgkin lymphoma (HL). METHODS: A cohort of 82 out of 260 patients with advanced stage HL enrolled in the International Validation Study (IVS), scored as 3 to 5 by the expert panel was included in the present report...
July 27, 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28741053/prediction-of-outcome-in-pediatric-hodgkin-lymphoma-based-on-interpretation-of-18-fdg-pet-ct-according-to-%C3%AE-suvmax-deauville-5-point-scale-and-ihp-criteria
#15
Emine Göknur Isik, Serkan Kuyumcu, Rejin Kebudi, Yasemin Sanli, Zeynep Karakas, Fatma Betul Cakir, Seher Nilgün Unal
OBJECTIVE: Minimizing side effects by using response-adopted therapy strategies plays an important role in the management of pediatric Hodgkin lymphoma (HL); however, the criteria for the definition of adequate or inadequate response are controversial. The aim of this study is to compare different methods of interpretation of (18)F-FDG-PET/CT (PET) in the prediction of disease outcome in order to determine the optimum method in this regard. METHODS: Baseline, interim and post-treatment PET scans of 72 children were interpreted according to revised International Harmonization Project criteria (IHP) and Deauville criteria...
November 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28711575/how-to-approach-a-patient-with-limited-stage-hodgkin-lymphoma-who-remains-pet-positive-at-the-end-of-chemotherapy-radiation-therapy
#16
REVIEW
Nmazuo W Ozuah, Ann S LaCasce
The use of 18-F fluorodeoxyglucose (FDG) positron emission tomography (PET) with computed tomography has emerged as a crucial tool for response-adapted therapy in Hodgkin lymphoma (HL). Although more studies have focused on the predictive value of an interim or early PET obtained after 2 cycles of chemotherapy, there are indications that the end of therapy PET might even be more predictive of outcome. The optimal treatment of patients with limited stage HL who are PET-positive after chemotherapy is unknown...
June 29, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28589704/modification-of-initial-therapy-in-early-and-advanced-hodgkin-lymphoma-based-on-interim-pet-ct-is-beneficial-a-prospective-multicentre-trial-of-355-patients
#17
MULTICENTER STUDY
Eldad J Dann, Osnat Bairey, Rachel Bar-Shalom, Tanya Mashiach, Elinor Barzilai, Abraham Kornberg, Luiza Akria, Tamar Tadmor, Kalman Filanovsky, Uri Abadi, Olga Kagna, Rosa Ruchlemer, Roxolyana Abdah-Bortnyak, Neta Goldschmidt, Ron Epelbaum, Netanel A Horowitz, David Lavie, Dina Ben-Yehuda, Ofer Shpilberg, Ora Paltiel
This multicentre study evaluated 5-year progression-free (PFS) and overall survival (OS) in early and advanced Hodgkin lymphoma (HL), where therapy was individualized based on initial prognostic factors and positron emission tomography-computed tomography performed after two cycles (PET-2). Between September 2006 and August 2013, 359 patients aged 18-60 years, were recruited in nine Israeli centres. Early-HL patients initially received ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) ×2. Depending on initial unfavourable prognostic features, PET-2-positive patients received additional ABVD followed by involved-site radiotherapy (ISRT)...
September 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28570287/usual-and-unusual-pitfalls-of-18f-fdg-pet-ct-in-lymphoma-after-treatment-a-pictorial-review
#18
Julien Dubreuil, Gilles Salles, Juliette Bozzetto, Jeremie Tordo, Loïc Djaïleb, Alina Berriolo-Riedinger, Julien Leenhardt, Francesco Giammarile, Michel Meignan, Andrea Skanjeti
Fluorine-18-fluorodeoxyglucose (F-FDG) PET/computed tomography (CT) is now a standard of care in initial staging and treatment evaluation of lymphomas. It is also used in the interim evaluation in diffuse large B cell lymphoma and Hodgkin lymphoma. However, several pitfalls may occur during or after treatment, because of the nonspecificity of F-FDG for lymphoma disease and treatment as immunotherapy, thus possibly induces misinterpretation and wrong treatment decision. The aim of this pictorial review is to provide an illustrated tutorial of the most frequent pitfalls found on F-FDG-PET/CT during or after treatment...
July 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28513853/association-between-textural-and-morphological-tumor-indices-on-baseline-pet-ct-and-early-metabolic-response-on-interim-pet-ct-in-bulky-malignant-lymphomas
#19
Fayçal Ben Bouallègue, Yassine Al Tabaa, Marilyne Kafrouni, Guillaume Cartron, Fabien Vauchot, Denis Mariano-Goulart
PURPOSE: We investigated whether metabolic, textural, and morphological tumoral indices evaluated on baseline PET-CT were predictive of early metabolic response on interim PET-CT in a cohort of patients with bulky Hodgkin and non-Hodgkin malignant lymphomas. METHODS: This retrospective study included 57 patients referred for initial PET-CT examination. In-house dedicated software was used to delineate tumor contours using a fixed 30% threshold of SUV max and then to compute tumoral metabolic parameters (SUV max, mean, peak, standard deviation, skewness and kurtosis, metabolic tumoral volume (MTV), total lesion glycolysis, and area under the curve of the cumulative histogram), textural parameters (Moran's and Geary's indices, energy, entropy, contrast, correlation derived from the gray-level co-occurrence matrix, area under the curve of the power spectral density, auto-correlation distance, and granularity), and shape parameters (surface, asphericity, convexity, surfacic extension, and 2D and 3D fractal dimensions)...
May 17, 2017: Medical Physics
https://www.readbyqxmd.com/read/28483373/optimisation-of-metabolic-criteria-in-the-prognostic-assessment-in-patients-with-lymphoma-a-multicentre-study
#20
M Del Puig Cózar-Santiago, J R García-Garzón, M Moragas-Freixa, M Soler-Peter, P Bassa Massanas, M Sánchez-Delgado, R Sanchez-Jurado, J E Aguilar-Barrios, R Sanz-Llorens, J Ferrer-Rebolleda
OBJECTIVE: To compare sensitivity, specificity and predictive value of Deauville score (DS) vs. ΔSUVmax in interim-treatment PET (iPET) and end-treatment PET (ePET), in patients with diffuse large B cell lymphoma (DLBCL), Hodgkin lymphoma (HL), and follicular lymphoma (FL). METHOD: Retrospective longitudinal multicentre study including 138 patients (46 DLBCL, 46 HL, 46 FL), on whom 3 (18)F-FDG PET/CT were performed: baseline, iPET, and ePET. Visual (DS) and semi-quantitative (ΔSUVmax) parameters were determined for iPET and ePET...
May 5, 2017: Revista Española de Medicina Nuclear e Imagen Molecular
keyword
keyword
118763
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"